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To determine the effect of changing public health 
surveillance methods on the reported epidemiology of Lyme 
disease, we analyzed Connecticut data for 1996–2007. Data 
were stratiﬁ  ed by 4 surveillance methods and compared. A 
total of 87,174 reports were received that included 79,896 
potential cases. Variations based on surveillance methods 
were seen. Cases reported through physician-based 
surveillance were signiﬁ  cantly more likely to be classiﬁ  ed 
as conﬁ   rmed; such case-patients were signiﬁ  cantly  more 
likely to have symptoms of erythema migrans only and to 
have illness onset during summer months. Case-patients 
reported through laboratory-based surveillance were 
signiﬁ  cantly more likely to have late manifestations only and 
to be older. Use of multiple surveillance methods provided 
a more complete clinical and demographic description 
of cases but lacked efﬁ   ciency. When interpreting data, 
changes in surveillance method must be considered.
L
yme disease, a multisystem disease caused by 
the spirochete bacterium Borrelia burgdorferi, is 
the most commonly reported vector-borne disease in 
Connecticut and in the United States (1). During 1996–
2007, Connecticut contributed 33,457 (15%) cases to the 
national surveillance case count, with a mean of 83.4 cases 
per 100,000 population reported annually, and consistently 
led the nation in reported annual incidence rate during 
the study period (2). Diagnosis of Lyme disease is based 
on clinical ﬁ  ndings, serologic evidence of infection, and 
history of exposure to Ixodes scapularis ticks. Early stages 
of illness are most readily diagnosed by identiﬁ  cation of 
erythema migrans. Later-stage illness can involve the 
musculoskeletal, neurologic, or cardiovascular systems. 
Positive serologic results are necessary for identifying and 
classifying patients with later manifestations.
During 1996–2007, the Connecticut Department of 
Public Health (CDPH) received Lyme disease reports 
through 4 surveillance methods: passive physician, active 
physician, enhanced laboratory, and mandatory laboratory. 
Physician-based surveillance (passive and active) was 
conducted during the entire study period and relied on 
health care providers to report new diagnoses of Lyme 
disease. Active surveillance comprised a voluntary network 
of health care providers who reported cases 1× per month. 
Enhanced laboratory surveillance, conducted during 1996–
1997, required participating Connecticut laboratories to 
send supplemental case report forms with each positive 
B. burgdorferi result to the ordering physician. In January 
1998, to study the effectiveness of a newly released Lyme 
disease vaccine, mandatory laboratory surveillance was 
implemented that required all laboratories to report positive 
and equivocal results to CDPH. Follow-up, conducted by 
CDPH staff, involved sending a letter and supplemental 
report form to the ordering physician. To assist the 
physician, demographic and patient-identifying information 
from the laboratory report was incorporated into the form. 
Mandatory laboratory surveillance ended after 2002 when 
the Lyme disease vaccine was removed from the market. In 
2007, mandatory reporting of positive Lyme disease results 
was reinstated for laboratories with electronic reporting 
capability. Two large commercial laboratories provided 
electronic reports. Follow-up was reestablished by using 
the previous method, i.e., CDPH staff sent a letter and 
supplemental report form to the ordering physician.
Public health surveillance methods for infectious 
diseases change over time, depending on program priorities 
and resources, advancements in diagnostic testing, 
modiﬁ  cations to surveillance case deﬁ  nitions, and changing 
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reporting modalities (e.g., electronic laboratory reporting). 
Lyme disease surveillance data provide a measure of the 
relative geographic distribution of this disease and its effect 
on public health in Connecticut and have been used to 
assess the effectiveness of control and prevention activities 
(3–5). These data also form part of the risk communication 
messages provided to the general public, advocacy groups, 
media, political leaders, health care providers, and public 
health professionals. We examined how surveillance 
method affected the classiﬁ   cation of reported clinical 
and demographic characteristics of case-patients and the 
incidence of Lyme disease in Connecticut, during 1996–
2007.
Materials and Methods
Surveillance Case Deﬁ  nition
Lyme disease reports were categorized by using the 
national surveillance case deﬁ  nition issued in 1996 (6). 
A case was deﬁ  ned as 1) physician report of erythema 
migrans of >5 cm in diameter or 2) at least 1 objective 
late manifestation (i.e., musculoskeletal, neurologic, 
or cardiovascular) with laboratory conﬁ  rmation  of 
infection with B. burgdorferi by enzyme immunoassay, 
immunoﬂ  uorescent assay, or Western immunoblot. CDPH 
classiﬁ  ed reports that did not meet the case deﬁ  nition as 
not a case. Because clinical information is required for 
case classiﬁ  cation, when supplemental follow-up reports 
were not returned, they were considered lost to follow-
up. The distinct report forms used for each surveillance 
method contained the following data elements: case-patient 
demographic characteristics (sex, age, race, ethnicity), 
clinical ﬁ  ndings (erythema migrans or late manifestations), 
seasonality, and case status. Seasons were deﬁ  ned as winter 
(December–February), spring (March–May), summer 
(June–August), and fall (September–November).
Data Collection
The statewide Lyme disease surveillance system was 
maintained by an average of 1.5 full-time employees. 
Reports were entered into the National Electronic 
Telecommunications System for Surveillance (NETSS), 
a public health surveillance information system that 
used Epi Info 6.0 (7). In 2007, NETSS and Microsoft 
Excel (Microsoft, Redmond, WA, USA) were used. 
Supplementary variables necessary for follow-up and 
maintenance of reports were added to the standard NETSS 
variables by CDPH staff and included health care provider 
name and contact information, license number, and origin 
of report.
A potential case could have been reported through 
>1 surveillance method. For consistency in classiﬁ  cation, 
the origin of case reports was entered in the following 
hierarchy: active surveillance, passive surveillance, 
enhanced laboratory surveillance, and mandatory laboratory 
surveillance. Data were cleaned and duplications were 
removed at the end of each year.
Data Analyzed
The following statistics were calculated across 
surveillance methods: annual mean number of reports and 
cases, annual incidence rates, proportion of reports by 
case status, demographic characteristics of case-patients, 
seasonality of cases, and clinical and laboratory ﬁ  ndings. 
Incidence per 100,000 population was determined by using 
decennial census data covering the year of data collection 
(1990 or 2000). Statistical tests were performed by using 
Epi Info 6.0. We used χ2 test with the Yates continuity 
correction. A p value <0.05 was considered signiﬁ  cant. 
The positive predictive value (PPV) of reports of potential 
cases was calculated for each type of surveillance method 
by determining the ratio of cases to reports.
Results
Overall Analysis
During 1996–2007, CDPH staff processed 87,174 
Lyme disease reports, of which 7,278 (8.3%) were 
duplicate entries and were removed from the database. 
A total of 79,896 individual reports were analyzed. Of 
these, 43,767 (54.8%) were reported through mandatory 
laboratory surveillance, 19,350 (24.2%) through passive 
physician surveillance, 13,040 (16.3%) through active 
physician surveillance, and 3,739 (4.7%) through enhanced 
laboratory surveillance. Overall, 33,457 (41.9%) reports 
were classiﬁ  ed as cases, and 26,318 (32.9%) as not cases; 
20,121 (25.2%) were lost to follow-up (Table 1). Except 
for calculation of PPV, reports classiﬁ  ed as lost to follow-
up were excluded from further analyses.
During 1996, Connecticut had 5,473 reports of 
Lyme disease. The number of reports increased with the 
successive implementation of enhanced and mandatory 
laboratory surveillance reporting, peaking at 12,947 in 2002 
(Figure 1). In 1998, the ﬁ  rst year of mandatory laboratory 
surveillance, the overall number of Lyme disease reports 
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Table 1. Number of Lyme disease reports, by status and 
surveillance method, Connecticut, 1996–2007* 
Status PS  AS  ELS  MLS  Total 
Case 12,185  8,666  1,949  10,657  33,457
Not a case  4,962  4,316  1,783  15,257  26,318
Lost to follow-up  2,203  58  7  17,853  20,121
Total† 19,350  13,040  3,739  43,767  79,896
*PS, passive physician surveillance 1996–2007; AS, active physician 
surveillance 1996–2007; ELS, enhanced laboratory surveillance 1996–
1997; MLS, mandatory laboratory surveillance 1998–2002 and 2007. 
†Positive predictive values: PS, 63.0; AS, 66.5; ELS, 52.1; MLS, 24.3; 
total, 41.9. RESEARCH
increased by 80.3%, cases increased by 49.4%, and 
physician-based reporting increased by 26.9% over the 
previous year; incidence was 104.5 cases per 100,000 
population. In 2003, the ﬁ  rst year after laboratory reporting 
ended, the overall number of reports decreased by 82.1%, 
cases decreased by 69.7%, and physician-based reporting 
decreased by 37.8% over the previous year; incidence was 
41.2 cases per 100,000 population. During 2003–2006, the 
period with no laboratory surveillance, the number of total 
reports dropped substantially to an annual mean of 2,411, a 
78.5% decrease from the 1999–2002 annual mean. In 2007, 
laboratory surveillance was reinstated for laboratories with 
the capability to electronically report results. The total 
number of reports increased by 228.3%, the number of 
cases increased by 71.0% over the previous year (Figure 1), 
and the incidence nearly doubled to 89.8 cases per 100,000 
population. An average of 16.0% more cases were reported 
through physician-based surveillance during years with 
mandatory laboratory reporting.
The PPV varied across surveillance methods and was 
highest for physician-based surveillance methods (Table 
1). Less than 25% of reports received through mandatory 
laboratory surveillance were classiﬁ   ed as cases. Cases 
reported through this method accounted for nearly one 
third (31.9%) of all cases during the study period.
Demographic Characteristics
The median age of case-patients was 38 years (range 
34–43 years). Case-patients <20 years of age were more 
likely to be reported through physician-based surveillance 
(p<0.001); laboratory-based surveillance was more 
likely to report case-patients >40 years of age (p<0.001) 
(Figure 2). Overall, whites accounted for 82.0% of cases, 
similar to the state’s racial distribution, and the distribution 
did not differ signiﬁ   cantly by surveillance method. 
Ethnicity data were available for approximately one 
third (32.6%) of case-patients; only 1.2% were reported 
as Hispanic. Laboratory-based surveillance reported an 
average of 32 Hispanic case-patients annually, compared 
with 20 reported through physician-based surveillance 
(Table 2). On average, 9.6% more male than female case-
patients were reported by each surveillance method.
Clinical Features
Of the 33,457 cases, 66.2% were characterized by 
erythema migrans only, 27.6% by >1 late manifestation and 
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Figure 1. Number of Lyme disease surveillance 
reports received and incidence per 100,000 
population, Connecticut, 1996–2007. White 
bar sections, passive surveillance; gold bar 
sections, active surveillance; blue bar sections, 
enhanced laboratory surveillance; green bar 
sections, mandatory laboratory surveillance; 
line, incidence, determined by using decennial 
census data encompassing the year data were 
reported.
Figure 2. Mean annual number of Lyme 
disease cases, by age group and surveillance 
method, Connecticut, 1996–2007. Black bar 
sections, physician-based surveillance; white 
bar sections, laboratory-based surveillance.Surveillance of Lyme Disease
positive laboratory ﬁ  ndings, and 6.2% by both (Tables 3, 
4). Overall, symptoms of erythema migrans only were more 
likely to be reported through physician-based surveillance 
than through laboratory-based surveillance (75.8% vs. 
50.3%; p<0.001). Conversely, late manifestations were 
more likely to be reported through laboratory-based 
surveillance than through physician-based surveillance 
(43.2% vs. 18.1%; p<0.001). Of all case-patients reported 
through laboratory-based surveillance, 30.5% had Lyme 
arthritis, compared with 13.4% of those reported through 
physician-based surveillance. Of cases characterized by late 
manifestations only, arthritis was most frequently reported 
(72.1%). Of late manifestation cases for which arthritis was 
reported, 74.0% were based on physician surveillance and 
70.8% on laboratory surveillance (p<0.001). Laboratory-
based surveillance was more likely to report case-patients 
with second- or third-degree atrioventricular block (p = 
0.051).
Seasonality
In 72.9% of cases, illness onset occurred during the 
summer (76.3% physician-based vs. 66.8% laboratory-
based cases) (Table 5). Erythema migrans occurred in 
84.2% of cases with onset during the summer. Erythema 
migrans was signiﬁ  cantly more likely to be reported during 
the summer through physician-based surveillance than 
through laboratory-based surveillance (71.3% vs. 28.7%; 
p<0.001). Late manifestations were 2× more likely to be 
reported through laboratory-based surveillance during the 
summer months (17.5% vs. 8.2%; p<0.001).
Discussion
In Connecticut, data obtained through 4 surveillance 
methods during 1996–2007 demonstrated that the 
epidemiology of Lyme disease is subject to variation by 
surveillance method. The number of reports, proportion of 
reports classiﬁ  ed as cases, incidence, and demographic and 
clinical characteristics of case-patients differed between 
physician-based and laboratory-based surveillance. 
Although some of the annual ﬂ   uctuation in reports 
and cases might be attributable to an actual increase or 
decrease in disease, the substantial changes seen indicate 
that the principal factor most likely resulted from changes 
in surveillance method over time. As these surveillance 
artifacts show, changes in surveillance methods can cause 
changes in trends. Therefore, the nature of the surveillance 
method and the effect of changes in the method are 
necessary to consider when interpreting the data.
Lyme disease surveillance methods ultimately rely on 
physicians to report the necessary clinical information to 
classify cases. Because health care providers in outpatient 
settings often underreport commonly seen illnesses (8,9), 
in Connecticut, follow-up for mandatory laboratory 
surveillance might help serve as a reminder system for 
physicians to report cases. This fact could explain the 
16.0% increase in the average annual number of cases 
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Table 2. Demographic characteristics of Lyme disease case-patients, by surveillance method, Connecticut, 1996–2007* 
Characteristic†
No. (%) case-patients  
PS, n = 12,185  AS, n = 8,666  ELS, n = 1,949  MLS, n = 10,657  Total, n = 33,457 
Sex          
  M  6,707 (55.0)  4,690 (54.1)  1,128 (57.9)  5,761 (54.1)  18,286 (54.7) 
  F  5,453 (44.8)  3,969 (45.8)  814 (41.8)  4,856 (45.6)  15,092 (45.1) 
  Unknown  25 (0.2)  7 (0.1)  7 (0.4)  40 (0.4)  79 (0.2) 
Race          
  White  10,402 (85.4)  6,772 (78.1)  1,440 (73.9)  8,811 (82.7)  27,425 (82.0) 
  Black  83 (0.7)  47 (0.5)  14 (0.7)  119 (1.1)  263 (0.8) 
  Asian/Pacific Islander  83 (0.7)  34 (0.4)  10 (0.5)  63 (0.6)  190 (0.6) 
  American Indian/Alaska Native  18 (0.1)  7 (0.1)  1 (0.1)  6 (0.1)  32 (0.1) 
  Other  83 (0.7)  17 (0.2)  1 (0.1)  32 (0.3)  133 (0.4) 
  Unknown  1,516 (12.4)  1,789 (20.6)  483 (24.8)  1,626 (15.3)  5,414 (16.2) 
Ethnicity          
  Hispanic  202 (1.7)  33 (0.4)  3 (0.2)  156 (1.5)  394 (1.2) 
  Non-Hispanic  7,051 (57.9)  884 (10.2)  16 (0.8)  2,550 (23.9)  10,501 (31.4) 
  Unknown  4,932 (40.5)  7,749 (89.4)  1,930 (99.0)  7,951 (74.6)  22,562 (67.4) 
*PS, passive surveillance; AS, active surveillance; ELS, enhanced laboratory surveillance; MLS, mandatory laboratory surveillance. 
†Median ages: PS, 34 y; AS, 36 y; ELS, 43 y; MLS, 42 y; total, 38 y. 
Table 3. Clinical manifestations of Lyme disease, by surveillance method, Connecticut, 1996–2007* 
Clinical manifestation 
No. (%) cases  
PS, n = 12,185  AS, n = 8,666  ELS, n = 1,949  MLS, n = 10,657  Total, n = 33,457 
Erythema migrans only  9,489 (77.9)  6,324 (73.0)  1,032 (53.0)  5,305 (49.8)  22,150 (66.2) 
Late manifestations only  2,059 (16.9)  1,725 (19.9)  763 (39.1)  4,678 (43.9)  9,225 (27.6) 
Both  637 (5.2)  617 (7.1)  154 (7.9)  674 (6.3)  2,082 (6.2) 
*PS, passive surveillance; AS, active surveillance; ELS, enhanced laboratory surveillance; MLS, mandatory laboratory surveillance. RESEARCH
reported through physician-based surveillance during years 
when laboratory surveillance was mandatory.
Our data showed that physician-based surveillance, 
combined with laboratory-based surveillance, resulted in 
more comprehensive clinical and demographic information 
and higher incidence of illness than each method alone. 
Of all reported cases, nearly one third (31.9%) originated 
through laboratory-based surveillance. However, use of 
laboratory-based surveillance is inefﬁ   cient: only 24.3% 
were classiﬁ  ed as cases. Case-patients reported through 
laboratory-based surveillance also differed signiﬁ  cantly 
in age groups, reporting older case-patients; clinical 
information, reporting more late stage illness; and seasonal 
data, reporting more cases during the fall and winter 
months. Our combined surveillance methods contributed 
to, and broadened, the overall epidemiologic description of 
Lyme disease in Connecticut.
This study has several limitations. First, laboratory-
based surveillance was difﬁ  cult to evaluate independently 
of physician-based surveillance. Because health care 
professionals could potentially report by using each of the 
surveillance methods, we used a hierarchy to help reduce 
bias toward 1 surveillance method over another. Second, 
because active surveillance providers volunteered to 
participate, these physicians were more likely to be those 
most interested in Lyme disease surveillance. Therefore, 
physicians who volunteered to participate in active 
surveillance might have been more likely to report cases in 
a strictly passive surveillance system.
To satisfy the sometimes conﬂ   icting goals of 
surveillance methods and allocation of public health 
resources, collection of case data needs to be streamlined. 
Two potential alternatives may be the following: modeling 
by using sampling schemes or greater use of electronic 
information systems, which is planned in Connecticut. 
Electronic laboratory reporting, automation of follow-up 
requests, and Web-based provider reporting will conserve 
resources, and provide incident data information demanded 
of public health agencies.
When determining which methods of Lyme disease 
surveillance to use, the purpose of that surveillance 
and available resources need to be considered. In Lyme 
disease–endemic states where the epidemiologic purpose 
might primarily be to monitor geographic, clinical, and 
demographic trends, intensive statewide surveillance is 
not essential. Rather, surveillance needs to be conducted 
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Table 4. Late manifestations of Lyme disease, by surveillance method, Connecticut, 1996–2007* 
Manifestation†
No. cases (%) 
PS, n = 2,059  AS, n = 1,725  ELS, n = 763  MLS, n = 4,678  Total, n = 9,225 
Lyme arthritis  1,448 (70.3)  1,353 (78.4)  532 (69.7)  3,318 (70.9)  6,651 (72.1) 
Bell palsy  454 (22.1)  259 (15.0)  143 (18.7)  814 (17.4)  1,670 (18.1) 
Radiculoneuropathy  117 (5.7)  131 (7.6)  84 (11.0)  501 (10.7)  833 (9.0) 
Lymphocytic meningitis  61 (3.0)  35 (2.0)  19 (2.5)  108 (2.3)  223 (2.4) 
Encephalitis/encephalomylitis  38 (1.5)  18 (1.0)  26 (3.4)  116 (2.5)  198 (2.1) 
Second- or third-degree heart block  40 (1.9)  26 (1.5)  10 (1.3)  58 (1.2)  134 (1.4) 
*PS, passive surveillance; AS, active surveillance; ELS, enhanced laboratory surveillance; MLS, mandatory laboratory surveillance. 
†May have included >1 late manifestation per case. Percentages do not add to 100%. 
Table 5. Lyme disease cases, by clinical manifestation, season, and surveillance method, Connecticut, 1996–2007 
Clinical manifestation/season 
No. (%) cases  
PS, n = 10,535*  AS, n = 8,281*  ELS, n = 1,767*  MLS, n = 8,685*  Total, n = 29,268 
All         
  Winter  278 (2.6)  244 (2.9)  76 (4.3)  548 (6.3)  1,146 (3.9) 
  Spring  1,029 (9.8)  923 (11.1)  154 (8.7)  1,118 (12.9)  3,224 (11.0) 
  Summer  8,121 (77.1)  6,234 (75.3)  1,276 (72.2)  5,707 (65.7)  21,338 (72.9) 
  Fall  1,107 (10.5)  880 (10.6)  261 (14.8)  1,312 (15.1)  3,560 (12.2) 
Erythema  migrans         
  Winter  84 (0.8)  56 (0.7)  7 (0.4)  73 (0.8)  220 (0.8) 
  Spring  741 (7.0)  624 (7.5)  34 (1.9)  425 (4.9)  1,824 (6.2) 
  Summer  7,315 (69.4)  5,500 (66.4)  993 (56.2)  4,164 (47.9)  17,972 (61.4) 
  Fall  739 (7.0)  515 (6.2)  78 (4.4)  501 (5.8)  1,833 (6.3) 
  Total  8,879 (84.3)  6,695 (80.8)  1,112 (62.9)  5,163 (59.4)  21,849 (74.7) 
Late  manifestations         
  Winter  194 (11.7)  188 (11.9)  69 (10.5)  475 (13.5)  926 (3.2) 
  Spring  288 (17.4)  299 (18.8)  120 (18.3)  693 (19.7)  1,400 (4.8) 
  Summer  806 (48.7)  734 (46.3)  283 (43.2)  1,543 (43.8)  3,366 (11.5) 
  Fall  368 (22.2)  365 (23.0)  183 (27.9)  811 (23.0)  1,727 (5.9) 
  Total  1,656 (15.7)  1,586 (19.2)  655 (37.1)  3,522 (40.6)  7,419 (25.3) 
*PS, passive surveillance; AS, active surveillance; ELS, enhanced laboratory surveillance; MLS, mandatory laboratory surveillance. Surveillance of Lyme Disease
consistently over time. Intensive surveillance efforts may 
even be counterproductive when not sustainable because 
of limited resources or when resources are diverted from 
other public health activities. Replacing traditional case-
reporting surveillance methods with less labor-intensive 
data collection methods, such as regular population-
based surveys, may be suitable for following trends and 
estimating disease (10).
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